you now share data with genentech and pfizer. goal is to incorporate all of this data into drug discovery. how is the drug invention going in health? anne: i love it. i am super excited about it. for people who have a disease, parkinson's is obviously one. fatigue or any of these autoimmune diseases, if we can use this data to translate into something meaningful, that is a spectacular reward for our customers. emily: what disorders are you focused on? i know you are doing a lot of work on lupus. anne: we are working on lupus with pfizer. we have a bunch that we are doing with big pharma companies. lupus and inflammatory bowel disease and parkinson's, we are about to launch a few others. emily: are you going to do human testing yourself here? anne: what we want to do and what we have learned from pharma, they will react best if we come to them with a target. there will be a compound with some clinical background, some data about how that's functioning. there is a higher likelihood of success if we can come with that level of infor